Marina Sagud, Dagmar Breznoscakova, Andreja Celofiga, Jana Chihai, Eka Chkonia, Dragana Ristic Ignjatovic, Lidija Injac Stevovic, Miloslav Kopecek, Katrin Kurvits, Nazar Kuzo, Judit Lazáry, Ramunė Mazaliauskienė, Djurdjica Mladina Perisa, Antoni Novotni, Georgi Panov, Uladzimir Pikirenia, Flavian Ștefan Rădulescu, Samvel Grant Sukiasyan, Māris Taube, Sonila Tomori, Alina Wilkowska, Carlos De Las Cuevas, Emilio J Sanz, Jose de Leon
OBJECTIVES: To compare the prevalence, regulations, and pharmacovigilance practices of clozapine use in Eastern European countries (except Russia). METHODS: Questionnaires and data from administrative databases (2016 and 2021), package inserts and national guidelines were collected from 21 co-authors from 21 countries. Reports of clozapine adverse drug reactions (ADRs) sent to the global pharmacovigilance database (VigiBase™) were analyzed from introduction to December 31, 2022...
September 30, 2023: Schizophrenia Research